Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S covers the month of June 2024, with the report dated June 24, 2024. The company is a foreign private issuer based in Denmark.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate action regarding warrant amendments rather than financial performance results.
Material Changes
On June 21, 2024, the Company entered into an Amendment to Warrants to Subscribe for Ordinary Shares Represented by American Depositary Shares (ADSs). This amendment affects warrants held by investors who purchased up to 9,726,898 ordinary shares (represented by 972,689 ADSs) under agreements dated December 18, 2023. The primary change converts the warrant exercise price per ordinary share from $0.707 to 4.799 Danish Kroner (DKK), subject to adjustment.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed in this report, other than the standard incorporation by reference of the warrant amendment exhibit.
Investor Verification Checklist
- Verify the exact terms of the Warrant Amendment filed as Exhibit 10.1.
- Confirm the conversion rate and adjustment mechanisms for the new exercise price of 4.799 DKK.
- Review the original securities purchase agreement from December 18, 2023, to understand the full context of the warrant holders.
- Check for any subsequent filings that may supersede the terms described in this 6-K.